User login
CHICAGO – Omega-3 polyunsaturated acid supplementation does not prevent recurrence of atrial fibrillation, according to a multisite, prospective, randomized trial presented by Dr. Peter R. Kowey of Lankenau Hospital at the annual scientific sessions of the American Heart Association.
Although previous small trials had hinted at a benefit, patients with persistent or paroxysmal atrial fibrillation who took high-dose, prescription omega-3 fatty acids (Lovaza, GlaxoSmithKline) for 24 weeks had a similar time to atrial fibrillation recurrence as did those who took placebo.
But that doesn’t negate the other, well established cardiovascular benefits of omega-3 fatty acids. In this video report, Dr. Kowey and Dr. Robert O. Bonow, the Goldberg Distinguished Professor at Northwestern University, discuss the implications.
CHICAGO – Omega-3 polyunsaturated acid supplementation does not prevent recurrence of atrial fibrillation, according to a multisite, prospective, randomized trial presented by Dr. Peter R. Kowey of Lankenau Hospital at the annual scientific sessions of the American Heart Association.
Although previous small trials had hinted at a benefit, patients with persistent or paroxysmal atrial fibrillation who took high-dose, prescription omega-3 fatty acids (Lovaza, GlaxoSmithKline) for 24 weeks had a similar time to atrial fibrillation recurrence as did those who took placebo.
But that doesn’t negate the other, well established cardiovascular benefits of omega-3 fatty acids. In this video report, Dr. Kowey and Dr. Robert O. Bonow, the Goldberg Distinguished Professor at Northwestern University, discuss the implications.
CHICAGO – Omega-3 polyunsaturated acid supplementation does not prevent recurrence of atrial fibrillation, according to a multisite, prospective, randomized trial presented by Dr. Peter R. Kowey of Lankenau Hospital at the annual scientific sessions of the American Heart Association.
Although previous small trials had hinted at a benefit, patients with persistent or paroxysmal atrial fibrillation who took high-dose, prescription omega-3 fatty acids (Lovaza, GlaxoSmithKline) for 24 weeks had a similar time to atrial fibrillation recurrence as did those who took placebo.
But that doesn’t negate the other, well established cardiovascular benefits of omega-3 fatty acids. In this video report, Dr. Kowey and Dr. Robert O. Bonow, the Goldberg Distinguished Professor at Northwestern University, discuss the implications.
FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION